Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital

Bisht, Niharika; Lohia, Nishant; Singh, Sankalp; Sarin, Arti; Mahato, Abhishek; Paliwal, Dharmesh; Sinha, Indranil; Bhatnagar, Sharad

doi:10.1055/s-0043-1777699

Cited by 2 publications

(1 citation statement)

References 33 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of different imaging modalities in the diagnosis of GBC is illustrated in Figure 2 . Some other studies on diagnostics and imaging modality are described in Table 4 [ 147 - 157 ].…”

Section: Studies On Diagnostics and Imagingmentioning

confidence: 99%

Gallbladder cancer: Progress in the Indian subcontinent

Kumar,

Sarangi,

Gupta

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is one of the commonest biliary malignancies seen in India, Argentina, and Japan. The disease has dismal outcome as it is detected quite late due to nonspecific symptoms and signs. Early detection is the only way to improve the outcome. There have been several advances in basic as well as clinical research in the hepatobiliary and pancreatic diseases in the West and other developed countries but not enough has been done in GBC. Therefore, it is important and the responsibility of the countries with high burden of GBC to find solutions to the many unanswered questions like etiopathogenesis, early diagnosis, treatment, and prognostication. As India being one of the largest hubs for GBC in the world, it is important to know how the country has progressed on GBC. In this review, we will discuss the outcome of the publications from India highlighting the work and the developments taken place in past several decades both in basic and clinical research.

show abstract

Section: Studies On Diagnostics and Imagingmentioning

confidence: 99%

Gallbladder cancer: Progress in the Indian subcontinent

Kumar,

Sarangi,

Gupta

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

show abstract

Gallbladder cancer (GBC) with Retroperitoneal Lymphadenopathy (RPLN) have outcomes similar to locally advanced disease if treated with radical intent.

Agrawal,

naik,

Priyanka

2024

Preprint

View full text Add to dashboard Cite

Introduction: Retroperitoneal lymphadenopathy is considered as metastatic disease in GBC, however some surgical series of radical surgery with RPLN dissection have shown results marginally inferior to those with non-RPLN lymph-node dissection. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC (40% ). There is dilemma in the intent of treatment to be offered in such cases. Hence we are reporting our series of GBC treated with first line CT and consolidation CTRT in responders with comparison of outcomes of patients with RPLN versus non-RPLN. Materials and methods: Non-metastatic advanced GBC with good performance status (KPS.80) were initiated on first line chemotherapy (CT, cisplatin-gemcitabine) and thereafter responders were evaluated by CT-angiography and PET-CT scan for resectability. If found unresectable, they were offered chemo-radiotherapy (CTRT) to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine @1250mg/m2 to GBC and regional lymphatics including RPLN. Thereafter boost dose of 9Gy/5# was given to GBC only. Response assessment was done using CT scan abdomen by RECIST criteria. Outcomes (overall survival) between the 2 groups (RPLN vs Non RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using spss v 20. Results: Amongst 189 patients of advanced non-metastatic GBC recruited from 2011–2022, 80 had RPLN. The demographic features of both groups were comparable. 68% patients were women, 30% underwent upfront stenting for obstructive jaundice, 90% had T3 and T4 disease and 45%, 30% and 25% had N0, N1, N2 in non-RPLN arm. Only 10% had undergone upfront laparoscopic staging and had pathological proven RPLN. 40% patients received 4 cycles CT only and 50% patients received 6 cycles or more, and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD) and 14.5% vs 3.7% were non-evaluable in Non-RPLN vs RPLN group respectively. 12% vs 6% could undergo radical surgery in Non-RPLN vs RPLN group (p = 0.03). The overall median overall survival was 9 months (95% CI 7.6–10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in Non-RPLN vs RPLN group respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN vs RPLN group respectively. Conclusions: Based on this analysis, we conclude that advanced non-metastatic GBC patients with RPLN have outcomes similar to those without RPLN if treated with radical intent.

show abstract

Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital

Cited by 2 publications

References 33 publications

Gallbladder cancer: Progress in the Indian subcontinent

Gallbladder cancer: Progress in the Indian subcontinent

Gallbladder cancer (GBC) with Retroperitoneal Lymphadenopathy (RPLN) have outcomes similar to locally advanced disease if treated with radical intent.

Contact Info

Product

Resources

About